Unavailability of high-dose methotrexate: situation normalised, recommendations lifted

date: 20/09/2023

The supply of high-dose methotrexate, used in oncology, was temporarily limited worldwide. The situation has since returned to normal, allowing the task force's recommendations to be lifted. 

The Federal Agency for Medicines and Health Products (FAMHP) has been informed by Teva Pharma Belgium that deliveries of Emthexate 50 mg/2 ml and Emthexate 5000 mg/50 ml, initially scheduled for mid-September, have now been made for several weeks. 

This means that the recommendations made by the task force at the beginning of July 2023 on the use of high-dose methotrexate can be lifted, and that the strategic stockpile does not need to be used.

The FAMHP is continuing to monitor the situation closely, both at national and European level, and is working with the National Institute for Health and Disability Insurance (INAMI), the Federal Public Service for Public Health and the Federal Strategic Stockpile until the availability of all high-dose methotrexate specialities is guaranteed.

Last updated on 20/09/2023